Abstract-We have shown previously that increased vascular endothelial expression of CYP4A2 leads to 20-hydroxyeicosatetraenoic (20-HETE)-dependent hypertension. The renin-angiotensin system is a key regulator of blood pressure.
2 0-Hydroxyeicosatetraenoic acid (20-HETE) is a cytochrome P450 (CYP)-derived arachidonic acid metabolite formed by members of the CYP4 family. It is endowed with unique biological activities relevant to the regulation of vascular tone, renal function, and blood pressure. The involvement of 20-HETE in hypertension has been significantly documented in animal models and humans. 20-HETE is a vasoconstrictor and natriuretic eicosanoid; hence, its contribution to the regulation of blood pressure depends on its sites of synthesis and action. In the vasculature, 20-HETE enhances the responsiveness to constrictor stimuli, including pressure, oxygen, phenylephrine, and endothelin 1, as well as inhibition of NO synthesis by mechanisms that include production of constrictor eicosanoids, inhibition of the smooth muscle cell large conductance Ca 2ϩ -activated K ϩ channel, and the sensitization of the contractile apparatus to [Ca 2ϩ ] through phosphorylation of MLC20. 1 We and others [2] [3] [4] demonstrated that, in circulatory districts other than the pulmonary, 20-HETE reduces endothelial-dependent vasorelaxation by uncoupling endothelial NO synthase. 5, 6 In the kidney, 20-HETE biosynthesis is prominent in the proximal tubule and thick ascending limb. It promotes natriuresis by inhibiting Na ϩ /K ϩ -ATPase activity in the proximal tubule and inhibiting the Na ϩ -K ϩ -2Cl Ϫ cotransporter in the thick ascending limb. 7 Consequently, enhanced production of 20-HETE within the vasculature, as in the spontaneously hypertensive rats 8, 9 or the androgen-dependent hypertensive rats 5, 10 and mice, 11 or attenuated synthesis and action in renal tubules as in Dahl salt-sensitive rats 12, 13 contributes to increases in blood pressure and hypertension. Accordingly, inhibition of vascular 5, 14 and induction of tubular 20-HETE synthesis 15 lower blood pressure in experimental hypertensive models. In humans, decreased urinary excretion of 20-HETE has been shown to correlate with salt sensitivity of hypertension, 16, 17 whereas increased urinary excretion of 20-HETE has been correlated with hypertension and with endothelial dysfunction. 18, 19 In all, these studies clearly implicated an important role for 20-HETE in the regulation of blood pressure.
The renin-angiotensin system (RAS) has been long recognized as a critical regulator of blood pressure and fluid homeostasis. Components of the RAS, including renin, angiotensin-converting enzyme (ACE), and angiotensin II (Ang II) type 1 receptor (AT 1 R) are generally expressed throughout the body in tissues that impact blood pressure control. Ang II, the product of sequential degradation of angiotensinogen by renin and ACE and the final effector of the RAS system, increases blood pressure by mechanisms that include vasoconstriction via AT 1 R activation in the vasculature and via increasing sympathetic tone and the release of arginine vasopressin and modulation of renal sodium and water reabsorption by stimulating renal AT 1 R, the production and release of aldosterone from the adrenal glands, or the sensation of thirst in the central nervous system. Blocking the synthesis or actions of Ang II lowers blood pressure in patients with hypertension. Equally, mice null for angiotensinogen, renin, ACE, and AT 1A R (the closest murine homologue to the human AT 1 R gene) exhibit a marked reduction in blood pressure, indicating the role of RAS in normal blood pressure homeostasis.
Given the characteristics of the RAS and the CYP4A-20-HETE pathways, interactions between these 2 systems are highly conceivable. To this end, Ang II has been shown to stimulate the release of 20-HETE in isolated preglomerular vessels. 20 Increased production of 20-HETE in the peripheral vasculature contributes to the acute vasoconstrictor response to Ang II, 21, 22 and chronic inhibition of 20-HETE biosynthesis attenuates the development of Ang II-dependent hypertension. 21, 23, 24 All together, these studies suggest that 20-HETE may contribute to the hypertensive actions of Ang II. We have shown recently that gene transfer-mediated endothelial-specific CYP4A2 overexpression leads to 20-HETEdependent hypertension in Sprague-Dawley rats. 25 We used this model to examine a possible interplay between the CYP4A2-20-HETE pathway and RAS. Here, we show that 20-HETE-induced hypertension in the CYP4A2-transduced rats is associated with RAS upregulation and is abrogated by ACE inhibition or AT 1 R blockade. This is the first demonstration to suggest that 20-HETE's prohypertensive property is mediated, at least in part, by activation of the RAS, possibly through induction of vascular ACE.
Methods and Materials
A detailed description of experimental protocols, methods, and materials is included in the online Data Supplement (please see http://hyper.ahajournals.org).
Results

20-HETE Stimulates ACE Expression in Endothelial Cells
A gene microarray was performed on mRNA extracted from cultured human endothelial cells treated with 20-HETE for 30 minutes. Among the few genes that were upregulated was ACE, which demonstrated a 5.76-fold increase compared with control (Table S1 and Figure S1 , available in the online Data Supplement at http://hyper.ahajournals.org). No significant changes were observed in the expression of ACE-2, angiotensinogen, AT 1 R, or Ang II type 2 receptor (AT2R; Figure S1 ). A real-time PCR analysis corroborated the microarray data; 20-HETE at a concentration of 5 nmol/L increased the ACE mRNA by 3-fold. 20-HETE-mediated induction of ACE mRNA was abolished by cotreatment with the 20-HETE antagonist 20-hydroxyeicosa-6(Z), 15(Z)-dienoic acid , demonstrating the specificity of the 20-HETE effect ( Figure S1 ).
AT 1 R Antagonist Reverses 20-HETE-Mediated Hypertension
The finding in cultured endothelial cells suggested the involvement of RAS in 20-HETE-mediated bioactions. Recently, we demonstrated that the lentivirus-mediated endothelial-specific transduction of CYP4A2 cDNA to Sprague-Dawley rats resulted in hypertension that was offset by treatment with HET0016, indicating that this model displays 20-HETEdependent hypertension. 25 In these rats, blood pressure significantly increased soon after injection of the lenti-VECAD-CYP4A2 and was greatly attenuated by daily treatment with HET0016 ( Figure 1A ). Blood pressure was not significantly altered in rats transduced with the lenti-VECAD-GFP (control transgene) treated with or without HET0016 ( Figure 1B) . At day 27 after infection, losartan was placed in the drinking water of untreated VECAD-CYP4A2-transduced rats. As seen in Figure 2A , losartan reduced blood pressure from 144Ϯ5 to 113Ϯ3 mm Hg. On cessation (72 hours after initiation) of losartan treatment, blood pressure returned to its high value (153Ϯ2 mm Hg) and remained high until the end of the experiment (146Ϯ4 mm Hg; Figure 2A ). Creatinine clearance decreased by 50% in the VECAD-CYP4A2-transduced rats when compared with the control VECAD-GFP-transduced rats. Treatment of VECAD-CYP4A2-transduced rats with HET0016 prevented the decrease in creatinine clearance ( Figure 1C ). The creatinine clearance data are indicative of reduced glomerular filtration rate consistent with the notion that 20-HETE is a renal vasoconstrictor and this action contributes to the hypertension in this model.
Endothelial CYP4A2 Overexpression Increases Plasma and Tissue Levels of Ang II
The drop in blood pressure after losartan administration suggested a role for the RAS in mediating 20-HETEdependent (HET0016-inhibitable) hypertension. Plasma renin concentration was not significantly different between control (VECAD-GFP-transduced), VECAD-CYP4A2-transduced, and HET0016-treated VECAD-CYP4A2-transduced rats ( Figure 2A ). However, plasma Ang II levels were 3-fold higher in VECAD-CYP4A2-transduced rats when compared with control VECAD-GFP-transduced rats ( Figure 2B ). Moreover, treatment with HET0016 reduced plasma Ang II levels (Pϭ0.059), suggesting that 20-HETE mediated this effect. Plasma Ang II levels in control rats (VECAD-GFPtransduced) treated with HET0016 or its vehicle amounted to 90Ϯ12 and 90Ϯ10 pg/mL, respectively ( Figure 2B) .
Similar results were obtained in aortic tissue. Ang II levels rose by 4-fold in aortas from VECAD-CYP4A2-transduced rats as compared with the control (Figure 2C ). Moreover, treatment of VECAD-CYP4A2-transduced rats with HET0016 reduced Ang II to levels not different from control. Interestingly, analysis of renal tissues from the same groups of rats clearly showed no significant differences in the levels of tissue Ang II ( Figure 2D ).
Endothelial CYP4A2 Overexpression Increases Vascular Ang II Levels and Expression of ACE and AT 1 R
Real-time PCR analysis of ACE and AT 1 R demonstrated significant increases in their mRNA levels in rats transduced with lenti-VECAD-CYP4A2 when compared with rats transduced with the control lenti-VECAD-GFP; these increases were prevented by daily treatment with HET0016 ( Figure 3A and 3B). In contrast, AT 2 R mRNA levels were not significantly altered by vascular CYP4A2 expression or 20-HETE levels ( Figure 3C ). Interestingly, treatment of control rats with HET0016 significantly reduced ACE mRNA levels as compared with untreated controls ( Figure 3A) . ACE protein (somatic ACE Ϸ170 kDa) levels increased by 2-fold in aorta of rats transduced with the VECAD-CYP4A2 as compared with control VECAD-GFP-transduced rats. Moreover, ACE protein levels were significantly decreased by treatment with HET0016 ( Figure 3D ), further indicating that 20-HETE contributed to the increased expression of ACE. AT 1 R protein levels showed a similar pattern, that is, a 2-fold increase in the aortas of VECAD-CYP4A2-transduced rats as compared with control, which was prevented by daily treatment with HET0016 ( Figure 3E) . Importantly, the expression of the AT 2 R was not affected by CYP4A2 overexpression or HET0016 treatment; levels of AT 2 R protein showed similar values in all of the experimental groups ( Figure 3F ).
Inhibition of ACE Prevents and Reverses
20-HETE-Mediated Hypertension
The possible involvement of the RAS in 20-HETE-mediated hypertension was further examined using lisinopril treatment before injection with lenti-VECAD-CYP4A2 and after the lenti-VECAD-CYP4A2-mediated increase in systolic blood pressure was established. As seen in Figure 4A , a bolus lenti-VECAD-CYP4A2 injection rapidly increased blood pressure within 3 days from 101Ϯ2 to 139Ϯ1 mm Hg, reaching 150Ϯ2 mm Hg at day 10 postinfection. At day 10, administration of lisinopril in the drinking water lowered blood pressure to control levels; however, blood pressure returned to its high levels on cessation of lisinopril treatment (day 19) and reached 163Ϯ3 mm Hg at day 37 postinfection. As shown previously, injection of lenti-VECAD-GFP to age-matched normotensive rats did not affect blood pressure ( Figure 4A ).
Another group of rats was given lisinopril 3 days before lenti-VECAD-CYP4A2 injection. In this group, blood pressure did not increase in response to the injection with lenti-VECAD-CYP4A2, as long as lisinopril was given in the drinking water. However, on cessation of lisinopril treatment (day 10 postinfection), blood pressure increased rapidly to 154Ϯ4 and 156Ϯ2 mm Hg at days 17 and 24 of the experiment, respectively ( Figure 4B ). To further demonstrate the 20-HETE dependency of blood pressure elevation in lenti-VECAD-CYP4A2-transduced rats, treatment with the 20-HETE antagonist, 20-HEDE, was initiated in this group at day 24 of the experiment. Blood pressure gradually decreased, reaching levels of 116Ϯ2 and 114Ϯ2 mm Hg at days 33 and 37 of the experiment ( Figure 4B ).
20-HETE Antagonist Attenuates 20-HETE Vascular Actions and CYP4A2-Induced Increase in ACE and Ang II Type 1 Expression
CYP4A2 expression increased by 40% in aortas and renal interlobar arteries from lenti-VECAD-CYP4A2-transduced rats as compared with those from control lenti-VECAD-GFP-transduced rats. CYP4A2 expression in arteries from lenti-VECAD-CYP4A2-transduced rats was not altered by treatment with 20-HEDE ( Figure 5A and 5B). The level of 20-HETE in renal interlobar arteries showed a similar pattern; it was higher in arteries from lenti-VECAD-CYP4A2-transduced rats as compared with arteries from lenti-VECAD-GFP-transduced rats (48.2Ϯ6.1 versus 34.8Ϯ3.0 ng/mg; nϭ4; PϽ0.05). CYP4A2 transduction had no significant effect on epoxygenase activity in renal interlobar arteries (levels of epoxyeicosatrienoic acidsϩdihydroxyeicosatrienoic acids in arteries from lenti-VECAD-GFP-and lenti-VECAD-CYP4A2-transduced rats were 75.27Ϯ9.94 and 69.93Ϯ13.95 ng/mg, respectively). Plasma levels of 20-HETE or epoxyeicosatrienoic acids were not altered by CYP4A2 transduction ( Figure S2 ). 20-HETE has been shown to sensitize renal arteries to constrictor stimuli, such as phenylephrine. 26 As seen in Figure  5C , renal interlobar arteries from lenti-VECAD-CYP4A2-transduced rats were more sensitive to phenylephrine than arteries from lenti-VECAD-GFP-transduced rats, as denoted by the EC 50 to phenylephrine (0.34Ϯ0.10 versus 1.03Ϯ0.03 mol/L; nϭ4; PϽ0.05). Treatment with 20-HEDE right-shifted the phenylephrine concentration-response curve, increasing (PϽ0.05) the EC 50 to 0.58Ϯ0.02 mol/L (nϭ4). The relaxation response of interlobar arteries to acetylcholine was significantly diminished in the arteries from lenti-VECAD-CYP4A2-transduced rats as compared with arteries from lenti-VECAD-GFPtransduced rats. Moreover, the relaxing response to acetylcholine was partially restored in arteries from lenti-VECAD-CYP4A2-transduced and 20-HEDE-treated rats ( Figure 5D ). Arteries from control rats treated with lisinopril had the same responses as arteries from control untreated rats. The addition of either lisinopril or losartan ex vivo attenuated 20-HETE-mediated impairment of acetylcholine-induced relaxation ( Figure  S3 ). ACE ( Figure 6A and 6B) and AT 1 R ( Figure 6C and 6D) expressions were higher in aortas and renal interlobar arteries from lenti-VECAD-CYP4A2-transduced rats as compared with those from control lenti-VECAD-GFP-transduced rats. Moreover, treatment with 20-HEDE significantly reduced the expression of ACE and AT 1 R. The vascular expression of AT 2 R was not different among the 4 groups (data not shown).
Discussion
The present study is the first to suggest that 20-HETE mediates its prohypertensive actions through the activation of the RAS, primarily by inducing ACE, leading to Ang IIdependent hypertension. The expression of CYP4 enzymes has been linked to the pathogenesis of hypertension in experimental animal models and humans through their catalytic activity as 20-HETE biosynthetic enzymes. The prohypertensive actions of 20-HETE are believed to be the result of its effect on vascular function. 20-HETE is a prominent eicosanoid in the microcirculation where it promotes constrictor mechanisms by sensitizing the smooth muscle to constrictor stimuli 1 and by limiting endothelial-dependent vasorelaxation, 2,4,5 most likely through interference with NO bioavailability via endothelial NO synthase uncoupling 3 and stimulation of superoxide production. 27 Consequently, increased expression of vascular 20-HETE leads to hypertension, whereas inhibition of vascular 20-HETE in experimental models of hypertension reduces blood pressure. Experimental models of hypertension that show increased vascular 20-HETE production include the spontaneously hypertensive rat 28, 29 and the androgen-induced hypertensive rats and mice. 5, 10, 11 Both models are Ang II dependent 30, 31 ; however, they present complex models for investigating the possible relationship between Ang II and 20-HETE in the control of blood pressure. Animal models that overexpress 20-HETE-producing CYP4 enzymes 6, 25 are hypertensive and, thus, provide good models for delineating the mechanisms contributing to 20-HETE-mediated hypertension. The observation that 20-HETE stimulates ACE expression in vitro raised the possibility that the RAS is part of 20-HETE prohypertensive actions.
The first indication of RAS involvement in 20-HETEmediated hypertension came from the observation that losartan decreased blood pressure in the CYP4A2-transduced rats. As reported previously 25 and substantiated in this study, this is an animal model that clearly shows 20-HETE-dependent hypertension based on the ability of the 20-HETE synthesis inhibitor or 20-HETE antagonist to prevent or reverse the hypertension, respectively. Once losartan was withdrawn, blood pressure rapidly returned to its high levels. Our interpretation of these data may be complicated by the involvement of other components of the RAS evoked by the development of hypertension. Thus, the effect of losartan could be independent of the initiating factor, that is, 20-HETE. However, the demonstration that injection of lenti-VECAD-CYP4A2 in the presence of lisinopril failed to increase blood pressure and that blood pressure remained low as long as lisinopril was present in the drinking water clearly suggested that RAS activation contributed to 20-HETEdependent hypertension. That the RAS system may be activated by 20-HETE is further supported by the following findings: (1) a 2-to 3-fold increase in vascular ACE and AT 1 R mRNA and protein expression in the CYP4A2-transduced rats compared with GFP-transduced rats; (2) suppression of elevated expression of ACE and AT 1 transduced rats that is reduced by treatment with the 20-HETE inhibitor. In addition, the observation that treatment of normotensive control rats with HET0016 decreased the basal expression levels of ACE suggests that 20-HETE may serve as an endogenous regulator of RAS expression through its action on ACE.
Because 20-HETE's prohypertensive properties stem from its actions in the vasculature and because CYP4A2 overexpression was targeted to the vasculature, it is possible that the involvement of the RAS in 20-HETE-dependent hypertension is primarily localized to the vasculature. The fact that Ang II levels in the kidney, as opposed to those in the vasculature, were not significantly elevated supports this notion. Evidence for the presence of RAS in the vascular wall, including renin, angiotensinogen, ACE, and Ang II receptors and the ability of vascular cells to produce Ang II, has been described. [32] [33] [34] The observation that in vitro 20-HETE potently and specifically induced ACE expression without significantly altering the expression of angiotensinogen, AT 1 R, or AT 2 R suggests that induction of endothelial ACE by 20-HETE may be a key step in the development of hypertension in this model, which is driven by endothelialspecific overexpression of the CYP4A2. ACE has been shown to be highly expressed in the vascular endothelium, whereas the media and the adventitia show little or low levels of ACE expression. 35 Kessler et al 36 have expressed ACE in the vascular endothelium of ACE null mice and demonstrated that endothelial ACE is essential for maintaining blood pressure, whereas Cole et al 37 showed that deletion of endothelial ACE does not alter blood pressure. Our study indicates that, under conditions of increased 20-HETE synthesis, vascular ACE expression is increased. More importantly, inhibition of 20-HETE synthesis or blockade of 20-HETE action prevented and reversed the increased expression of ACE in the VECAD-CYP4A2-transduced rats, strongly implicating 20-HETE as a modulator of ACE expression. Our data also indicate that the increase in 20-HETE in VECAD-CYP4A2-transduced rats is associated with an increase in vascular AT 1 R expression. Such an increase could be the consequence of increased Ang II levels. The mechanism by which 20-HETE induces ACE expression is unknown. We have shown that the 20-HETE effect on endothelial cell NO production and nuclear factor-B activation is mediated through tyrosine kinase/epidermal growth factor receptor-and mitogen-activated protein kinase (extracellular signal-regulated kinase 42/44)-dependent inhibitor of nuclear factor-B kinase activation 38 ; preliminary data suggested that induction of ACE by 20-HETE in endothelial cells is also inhibitor of nuclear factor-B kinase mediated (J. Cheng et al, unpublished data, 2010). In summary, it is possible that the induction of ACE within the vascular endothelium sets in motion an increase in vascular Ang II and that such increases contribute, possibly through Ang II-AT 1 R interactions, to the hypertension brought about by increasing vascular 20-HETE levels. The ability of a 20-HETE inhibitor or antagonist to prevent/ reverse hypertension, the capacity of an AT 1 R blocker to reduce blood pressure, and the ability of an ACE inhibitor to prevent hypertension in this model of 20-HETE-dependent hypertension support this possibility. However, the spatial and temporal relationships between 20-HETE and ACE induction and the causative role of 20-HETE-induced endo- thelial ACE expression in hypertension need to be further explored.
Perspectives
The Animal Experimentation. All experimental protocols were performed following an IACUC-approved protocol in accordance with the NIH Guide for the Care and Use of Laboratory Animals. Sprague-Dawley rats (9 to 10 weeks old, 225-250 g body weight) were used in all experiments. Rats were fed normal chow diet and had access to water ad libitum. Vascular endothelium was targeted by lentiviruses carrying the CYP4A2 or GFP constructs under the control of the endothelium specific promoter VE-cadherin (VECAD-4A2 and VECAD-GFP, respectively) (Lentigen, Baltimore, MA) as previously described 5 . Lentiviruses were injected into the left renal artery (200 µL of 10 9 TU/mL in saline) and the tail vein (75 µl of 10 9 TU/mL in saline) under anesthesia with sodium pentobarbital (65 mg/kg body weight, ip). The following experimental protocols were used: Protocol 1: The experiment was carried out for 45 days. Rats (n=16) were divided into four groups: A) rats were injected with lenti-VECAD-CYP4A2 at day 0; at day 27, losartan (100 mg/kg/day) was given in the drinking water for 3 days. B) rats were injected with lenti-VECAD-CYP4A2 at day 0 and co-treated with daily injections of the CYP4A selective inhibitor HET0016 (10 mg/kg body weight/day) for the duration of the experiment. C) rats were injected with lenti-VECAD-GFP at day 0. D) rats were injected with lenti-VECAD-GFP at day 0 and co-treated with daily injections of HET0016. Protocol 2: The experiment was carried out for 37 days. Rats (n=16) were divided into four groups: A) rats were injected with lenti-VECAD-GFP at day 0; B) rats were given lisinopril (10 mg/kg/day) in the drinking water 3 days prior to a bolus injection of lenti-VECAD-GFP and thereafter; C) rats were injected with lenti-VECAD-CYP4A2 at day 0; at day 10, lisinopril (10 mg/kg/day) was given in the drinking water for 9 days (day 19 of the experiment); D) rats were given lisinopril (10 mg/kg/day) in the drinking water 3 days prior to a bolus injection of lenti-VECAD-CYP4A2 and 10 days after lentivirus injection; at day 24 of the experiment, the 20-HETE antagonist, 20-HEDE (10 mg/kg/day), was administered intraperitoneally till the end of the experiment. Systolic blood pressure was monitored by the tail cuff method before lentiviral injection and during the length of the experiment. Values within ± 10% of their mean blood pressure measurements were obtained. At the end of all experiments, rats were euthanized and kidneys, aortae and renal interlobar arteries were collected for biochemical analyses.
Sources of Funding
Measurement of Plasma/Tissue Angiotensin II, PRC and ACE.
For measurements of ACE activity, 250 µl of venous blood sample were collected at room temperature without the addition of anticoagulants. Blood was centrifuged at 2500 g for 10 min at Real time PCR. Total RNA was isolated from aorta and cell samples using the RNeasy Mini Kit (Qiagen) and quantified with NanoDrop (ThermoScientific). RT reaction of total RNA (500 ng) was performed using the Superscript III FirstStrand Synthesis System (Invitrogen) according to the manufacturer's instructions. Specific primers were designed based on published sequences (Gene bank). PCR primer sequences were as follows: angiotensin converting enzyme (ACE, rat): sense 5'-CGG GAC GTG GCC ATT ATA TT-3', antisense 
Western Blot analysis.
Frozen interlobar arteries and aortae were pulverized under liquid nitrogen and homogenized in 10 mmol/L potassium phosphate buffer, pH 7.2, containing 25 mmol/L sucrose, 0.1% NP-40, 1 mmol/L EDTA and a cocktail of proteinase inhibitors. The homogenates were centrifuged at 1000g for 15 min and the supernatant was used for Western blot analysis. Proteins (20-30 µg) were separated by SDS/polyacrylamide gel electrophoresis at 75 V for 2-3 h at room temperature and then transferred electrophoretically to a nitrocellulose membrane. Membranes were incubated with the following primary and secondary antibodies: mouse anti-ACE1 monoclonal antibody (1:500; Abcam, ab11734), rabbit anti-AT1 polyclonal antibody (1:500; Abcam, ab18799), rabbit anti-AT2 polyclonal antibody (1:800; Abcam, ab19134), goat anti-rat CYP4A1 polyclonal antibody (1:3000; Daiichi Chemical Co, Japan), goat anti-rabbit IgG (1:2000) and goat anti-mouse IgG (1:1000). Immunoreactive proteins were detected using the ECL Plus detection system (Amersham Life Sciences) according to the manufacturer's instructions. Anti β-actin was used to normalize for loading variations.
LC-MS/MS analysis of vascular and plasma 20-HETE, EETs, and DHETs.
Renal interlobar arteries were incubated in 1 ml oxygenated Krebs buffer (37°C, 60 min) with 1 mmol/L NADPH. Reactions were terminated by acidification to pH 4 with acetic acid. Thereafter, 500 pg of internal standard mix (d11-11,12-DiHETrE; d11-8(9)-EET; d6-20-HETE, d8-11(12)-EET )were added as internal standards to each sample. 20-HETE was extracted with twice the volume of ethyl acetate (3 times), dried under nitrogen and stored at -80°C for LC/MS/MS analysis. NaOH (1 mol/L, 100 µl) was added to the arteries after extraction for their dissolution and determination of protein concentration (BioRad, Hercules, CA). For measurements in plasma, acidified water (pH 4) and 1 ng of internal standard mix were added to thawed rat plasma (100-300 µl) and first extracted with 5 vol chloroform/methanol (2:1) followed by addition of 2x1 vol chloroform. The chloroform layers were combined dried under nitrogen. Alkali hydrolysis was performed by adding 1 ml 1M NAOH to each sample followed by 90 min incubation at room temperature. Samples were neutralized with 1M HCL and loaded onto preconditioned Strata-X columns (Phenomenex, Torrance, CA), washed with 2 ml 10% methanol, and eluted with 2 ml of 100% methanol. All samples were dried under nitrogen and stored at -80°C until LC/MS/MS analysis. Identification and quantification of 20-HETE, EETs, and DHETs were performed with a Q-trap 3200 linear ion trap quadrupole LC/MS/MS equipped with a Turbo V ion source operated in negative electrospray mode (Applied Biosystems, Foster City, CA). Multiple reaction monitoring was used with a dwell time of 25 or 50 ms for each compound, with source parameters: ion spray voltage, -4500 V; curtain gas, 40 U; ion source gas flow rate 1, 65 U and 2, 50 U; and temperature of 600ºC. Synthetic -standards (Cayman Chemical, Ann Arbor, MI) were used to obtain standard curves (5-500 pg) for for each eicosanoid and internal standard. The amounts in each sample were corrected for loss during extraction and normalized by protein amount or plasma volume.
Measurements of vascular reactivity and endothelial function.
Renal interlobar arteries (~230 µm, internal diameter) were cut into ring segments (2 mm) and mounted on wires in the chambers of a multivessel myograph (JP Trading, Aarhus, Denmark) filled with oxygenated Krebs' buffer (37°C). After 30 to 60 min of equilibration, the vessels were set to an internal circumference equivalent to 90% of that which they would have in vitro when relaxed under a transmural pressure of 80 mm Hg. Isometric tension was monitored continuously before and after experimental interventions. A cumulative concentrationresponse curve to phenylephrine (10 -9 to 5x10 -5 mol/L) was constructed. The phenylephrine-induced increase in isometric tension was expressed as the percentage of the maximum contraction achieved. For measurements of the relaxing response to acetylcholine, the vascular preparations were contracted with phenylephrine to 80% of maximum contraction. When the contractile response was stabilized, a cumulative concentration-response curve to acetylcholine (10 -9 to 5x10 -5 mol/L) was constructed in the presence of 20-HETE (50 nM) with and without lisinopril ( ) or losartan (). Cumulative concentrationresponse curve to nitroprusside (10 -9 to 5x10 -5 mol/L) were performed in phenylephrine-preconstricted arteries in the presence of 20-HETE (1 µM) or 20-HEDE (1 µM). 20-HETE and 20-HEDE were added to the bath 15 min prior to phenylephrine.
Statistical analysis.
The data are presented as mean ± standard error (SE). Statistical significance (p<0.05) between the experimental groups was determined by the Fisher method of analysis for multiple comparisons. For comparison between treatment groups, the Null hypothesis was tested by a single factor analysis of variance (ANOVA; Dunnett's Multiple Comparison Test) for multiple groups or unpaired t-test for two groups.
RESULTS
Gene Microarray and real time PCR. The expression of 100 genes was assessed in mRNA extracted from HMVEC treated with and without 20-HETE (1 nM) for 30 min using the human GEarray microarray (SA Biosciences). The results are summarized in Table S1 . A real-time PCR analysis corroborated the microarray data; 20-HETE at a concentration of 5 nM increased ACE mRNA by 3-fold. 20-HETE-mediated induction of ACE mRNA was abolished by co-treatment with the 20-HETE antagonist 20-HEDE, demonstrating the specificity of the 20-HETE effect ( Figure S1 ). No significant changes were observed in the expression of ACE-2, angiotensinogen, AT1R or AT2R ( Figure S1 ).
Plasma levels of 20-HETE, EETs and DHETs. The total Levels of 20-HETE, EETs and DHETs were measured after alkali hydrolysis (free+esterified). There were no significant differences in the levels of these eicosanoids between GFP and CYP4A2-transduced rats. 20-HETE. As seen in Figure S1 , 20-HETE levels were 1.01±0.20 and 0.78±0.22 ng/ml in lenti-VECAD-GFP and Lenti-VECAD- 
